I would like Roth Capital to do the valuation, they had a target of $4.50 in Nov 2016. The board seems to have forgotten this.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025